Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Childs Nerv Syst ; 25(5): 627-30, 2009 May.
Artigo em Inglês | MEDLINE | ID: mdl-19296115

RESUMO

INTRODUCTION: We report a patient who suffered from brainstem injury following ventriculoperitoneal (VP) shunt placement in the fourth ventricle. DISCUSSION: A 20-year-old man with complex hydrocephalus and trapped fourth ventricle underwent a suboccipital placement of a VP shunt. Postprocedure patient developed double vision. Magnetic resonance imaging showed that the catheter was penetrating the dorsal brainstem at the level of the pontomedullary junction. Patient was referred to our Neuroendoscopic Clinic. Physical exam demonstrated pure right VI cranial nerve palsy. Patient underwent flexible endoscopic exploration of the ventricular system. Some of the endoscopic findings were severe aqueductal stenosis and brainstem injury from the catheter. Aqueductoplasty, transaqueductal approach into the fourth ventricle, and endoscopic repositioning of the catheter were some of the procedures performed. Patient recovered full neurological function. The combination of endoscopic exploration and shunt is a good alternative for patients with complex hydrocephalus. A transaqueductal approach to the fourth ventricle with flexible scope is an alternative for fourth ventricle pathology.


Assuntos
Tronco Encefálico/lesões , Doenças dos Nervos Cranianos/etiologia , Quarto Ventrículo/cirurgia , Hidrocefalia/cirurgia , Neuroendoscopia , Derivação Ventriculoperitoneal/efeitos adversos , Tronco Encefálico/patologia , Tronco Encefálico/cirurgia , Doenças dos Nervos Cranianos/complicações , Diplopia/etiologia , Diplopia/patologia , Quarto Ventrículo/patologia , Humanos , Hidrocefalia/patologia , Imageamento por Ressonância Magnética , Masculino , Neuroendoscopia/métodos , Procedimentos Neurocirúrgicos/métodos , Resultado do Tratamento , Derivação Ventriculoperitoneal/métodos , Adulto Jovem
2.
Monaldi Arch Chest Dis ; 63(2): 88-92, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16128223

RESUMO

BACKGROUND: This study sets out to estimate the prevalence and the degree of severity of bronchial obstruction in an adult population with three different diagnostic criteria: the European Respiratory Society (ERS), the American Thoracic Society (ATS), and the World Health Organization (WHO) defined as Global Obstructive Lung Disease (GOLD). METHODS: 1514 subjects underwent complete medical evaluation and spirometry. RESULTS: The prevalence of bronchial obstruction was respectively 27.5 % (ERS), 33% (GOLD), and 47.3 % (ATS). The prevalence of bronchial obstruction in the smoker group was 33.4% (ERS), 38.1% (GOLD), and 52.3% (ATS). The prevalence of obstruction in the ex-smoker group was 33% (ERS), 41.4% (GOLD), and 57.1% (ATS). The prevalence of obstruction in the non-smoker group was 21.1% (ERS), 24.9% (GOLD), and 38.6% (ATS). CONCLUSIONS: The results show that the prevalence of airway obstruction increases proportionally with age; the cigarette smoking represents an important conditioning factor. These observations warrant the necessity of a more complete and multi-parametric analysis in the evaluation of patients with airway obstruction using methodologies that explore the functional state and the risk factors that cause the airway obstruction.


Assuntos
Pneumopatias Obstrutivas/epidemiologia , Adulto , Fatores Etários , Feminino , Volume Expiratório Forçado/fisiologia , Humanos , Itália/epidemiologia , Pneumopatias Obstrutivas/classificação , Masculino , Pessoa de Meia-Idade , Pico do Fluxo Expiratório/fisiologia , Prevalência , Doença Pulmonar Obstrutiva Crônica/classificação , Doença Pulmonar Obstrutiva Crônica/epidemiologia , Índice de Gravidade de Doença , Fumar/epidemiologia , Espirometria/estatística & dados numéricos , Capacidade Vital/fisiologia
3.
Aliment Pharmacol Ther ; 19(3): 339-47, 2004 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-14984381

RESUMO

BACKGROUND: An early virological response to interferon-alpha treatment is a strong predictor of sustained response, but it has never been exploited to stratify patients in clinical trials. AIM: To evaluate the efficacy of amantadine plus interferon-alpha compared with interferon-alpha alone in naive patients with chronic hepatitis C who were randomized on the basis of the early virological response to interferon-alpha. METHODS: One hundred and eighty-one patients received recombinant interferon-alpha2a (3 MU three times weekly) for 2 months and 164 were evaluated for early (i.e. month 2) virological response. Hepatitis C virus (HCV) RNA-negative patients (n = 66) were randomized to receive 3 MU of interferon-alpha three times weekly, with or without amantadine (200 mg/day); HCV RNA-positive patients (n = 98) were randomized to receive 6 MU of interferon-alpha three times weekly, with or without amantadine (200 mg/day). HCV RNA-positive patients at 6 months discontinued treatment, and all others completed 12 months. RESULTS: At month 6, HCV RNA-negative patients made up 54.2% of the interferon + amantadine group and 42.0% of the monotherapy group (P = 0.07). At month 12, HCV RNA-negative patients made up 38.5% of the interferon + amantadine group and 28.4% of the monotherapy group (N.S.). The sustained virological response rates were 21.6% and 20.9%, respectively (N.S.). CONCLUSION: The addition of amantadine does not enhance the sustained virological response to interferon-alpha in naive patients with chronic hepatitis C; however, an additive effect of amantadine occurs in the first 6 months, mainly in patients without an early response to monotherapy. Early response to interferon-alpha is a strong predictor of sustained virological response.


Assuntos
Amantadina/uso terapêutico , Antivirais/uso terapêutico , Hepatite C Crônica/tratamento farmacológico , Interferon-alfa/uso terapêutico , Adolescente , Adulto , Idoso , Combinação de Medicamentos , Feminino , Humanos , Interferon alfa-2 , Masculino , Pessoa de Meia-Idade , Proteínas Recombinantes , Resultado do Tratamento
4.
Panminerva Med ; 42(1): 23-6, 2000 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11019600

RESUMO

BACKGROUND: To determine whether an excessive, prolonged and, above all, unusual physical exertion could be associated with episodes of mild hypoglycaemia in non-insulin-dependent diabetes mellitus (NIDDM) patients treated with glibenclamide. EXPERIMENTAL DESIGN: 11 months of observation with retrospective analysis of patient personal diaries to determine the hypoglycaemic risk. SETTING: Diabetic Unit-Department of Medicine and Aging-Chieti University School of Medicine. PATIENTS: We enrolled 340 NIDDM outpatients adjusted for sex, age, body mass index, alcohol intake and oral treatment regimen with glibenclamide. PATIENTS were tested monthly for circadian blood glucose profiles and glycosylated hemoglobin. Mild hypoglycaemia was defined on the basis of blood glucose values < 2.8 mmol/l associated with mild autonomic symptoms, without requiring external assistance. Each diabetic patient filled personal diary indicating the therapy regimen and the characteristics of eventual hypoglycaemic episodes occurring during the observation period. RESULTS: 21.8% of NIDDM patients experienced one or two episodes of mild hypoglycaemia during the observation period. The analysis of the patients' diaries showed that 60% of the hypoglycaemic episodes was associated with excessive, prolonged and unexpected physical exertions. Within this group, about 70% of the episodes occurred during a holiday ("holiday hypoglycaemia"). After analyzing the socio-demographic and clinical characteristics of the diabetic patients reporting hypoglycaemic events, we found a higher risk for "holiday hypoglycaemia" in patients with a lower educational level, with a sedentary occupation or among the ex-farmers. CONCLUSIONS: As resulted in the present study, unexpected physical exertions may represent a relevant cause of mild hypoglycaemia in diabetic patients receiving oral antidiabetic therapy. However, this hypoglycaemic cause may have been underestimated in the literature. Educational programs conducted by general practitioners or diabetologists could be useful for the patients in reducing the number of mild hypoglycaemic episodes.


Assuntos
Diabetes Mellitus Tipo 2/sangue , Glibureto/uso terapêutico , Hipoglicemia/etiologia , Hipoglicemiantes/uso terapêutico , Esforço Físico/fisiologia , Diabetes Mellitus Tipo 2/tratamento farmacológico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos
5.
Ann Clin Lab Sci ; 34(1): 94-8, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15038674

RESUMO

The association of gastroesophageal reflux, esophagitis, and asthma has been studied for a long time, but the results are often conflicting. The aim of this study is to evaluate the prevalence of bronchial asthma and the presence of extra-esophageal symptoms in subjects with endoscopically-documented reflux esophagitis. Forty patients were divided into 2 groups: group A (22 patients) affected by endoscopically-documented esophagitis, and group B (18 patients) with positive endoscopic examination for other pathologies of the gastroenteric tract. All of the patients underwent complete medical examination, skin-prick tests, esophageal-gastric-endoscopy, and pulmonary function tests (basal and after methacholine). The prevalence of asthma was 30% in group A vs 10% in group B (odds ratio = 2.57; confidence interval = 0.75-10.25). Relationships between chronic cough and esophagitis (p<0.01) and between chronic cough and asthma (p<0.05) were found. No significant relationships were observed between esophagitis and the other respiratory symptoms considered (wheezing, chest tightness, hoarseness, bronchospasm, and dysphagia). The results confirm the increased prevalence of asthma in patients with esophagitis and they emphasize the role of gastroesophageal reflux as a trigger factor for asthma. Chronic cough represents an important symptom of asthma in subjects with esophagitis.


Assuntos
Asma/epidemiologia , Asma/etiologia , Esofagite Péptica/complicações , Adulto , Endoscopia do Sistema Digestório , Esofagite Péptica/diagnóstico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência
6.
Sci Total Environ ; 270(1-3): 43-8, 2001 Apr 10.
Artigo em Inglês | MEDLINE | ID: mdl-11327397

RESUMO

The aim of the study was to assess the seasonal variability of non-specific bronchial reactivity (NSBR) evaluated with methacholine in asthmatic farmers allergic to pollens. Twenty farmers (16 male and four female) with allergy to pollens, e.g. 'Graminae' and 'Parietaria', entered the study. None of the patients had been previously treated with specific immunotherapy. Patients underwent a methacholine challenge at the first visit and then in the subsequent seasons. Four groups of tests were obtained according to the period when the challenge was performed. Group 1: challenges performed in December, January and February; group 2 in March, April and May; group 3 in June, July and August; group 4 in September, October and November. PD20 values were expressed as the natural logarithm of the cumulative dose of methacholine causing at least a 20% fall in FEV1. Bronchial hyperreactivity was highest in summer, followed by spring and autumn; in winter it was much lower. Multiple group analysis (ANOVA) showed statistically significant differences between the groups (P < 0.01). When the groups were compared individually, statistically significant differences existed only between group 1 (winter) and each of the other groups, respectively 2 (spring) (P = 0.02), 3 (summer) (P = 0.004) and 4 (autumn) (P = 0.02). The results underlined the importance of allergic inflammation in determining changes in NSBR. In the region where the study was carried out (central Italy), the grass and Paretaria pollination lasts from March to November. Therefore, farmers had a progressive increase in NSBR from spring to summer and a decrease in fall as a consequence of the varying pollen concentration in different seasons. The level of allergen exposure is, in fact, the main factor that determines the severity of bronchial inflammation, thus affecting NSBR.


Assuntos
Agricultura , Alérgenos , Asma/imunologia , Testes de Provocação Brônquica , Feminino , Humanos , Itália , Masculino , Pólen , Estações do Ano
7.
Clin Ter ; 153(5): 317-21, 2002.
Artigo em Italiano | MEDLINE | ID: mdl-12510415

RESUMO

PURPOSE: Insufficient data exist to evaluate the comparative effects of inhaled corticosteroids versus leukotriene receptor antagonists on airway inflammation and remodelling. The aim of the study was to evaluate the effectiveness and safety of montelukast versus budesonide at different doses on bronchial reactivity in mild-asthmatic adult patients. PATIENTS AND METHODS: A total of 40 patients were randomly assigned to a different treatment and divided in 2 treatment groups (A, B) as follows: A-10 mg of montelukast daily; B-400 mg of budesonide twice a day. RESULTS: We studied 40 subjects (21 males, 19 females) divided in two groups of 20 subjects each: group A with mean age 25.16 +/- 7.68 years, group B with mean age 26.18 +/- 6.15 years. After 16 weeks of treatment in the group A the PC20 (provocative concentration of methacholine which cause a fall of FEV1 > or = 20%) was 620.12 +/- 140.54 micrograms/mL significantly highly compared to basal value of 315.75 +/- 100.16 micrograms/mL (p < 0.02). In the group B the PC20 was 795.67 +/- 312.76 micrograms/mL significantly highly compared to basal value of 342.87 +/- 132.38 micrograms/mL (p < 0.001). We not found differences in FEV1, FVC e PEF before and after the treatment. CONCLUSIONS: Montelukast may be considered a valid alternative in the treatment of mild-persistent asthma, both for the benefits on bronchial reactivity and for the great advantage of the once-daily dosage, which consistently improves the compliance with the chronic treatment of the disease.


Assuntos
Acetatos/uso terapêutico , Antiasmáticos/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Asma/tratamento farmacológico , Broncodilatadores/uso terapêutico , Budesonida/uso terapêutico , Antagonistas de Leucotrienos/uso terapêutico , Quinolinas/uso terapêutico , Acetatos/administração & dosagem , Acetatos/efeitos adversos , Adulto , Antiasmáticos/administração & dosagem , Antiasmáticos/efeitos adversos , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/efeitos adversos , Asma/fisiopatologia , Hiper-Reatividade Brônquica/tratamento farmacológico , Broncodilatadores/administração & dosagem , Broncodilatadores/efeitos adversos , Budesonida/administração & dosagem , Budesonida/efeitos adversos , Doença Crônica , Ciclopropanos , Feminino , Humanos , Antagonistas de Leucotrienos/administração & dosagem , Antagonistas de Leucotrienos/efeitos adversos , Masculino , Quinolinas/administração & dosagem , Quinolinas/efeitos adversos , Índice de Gravidade de Doença , Sulfetos , Resultado do Tratamento
8.
Clin Ter ; 155(1): 29-31, 2004 Jan.
Artigo em Italiano | MEDLINE | ID: mdl-15147079

RESUMO

The leptin system is a major regulator of food intake and metabolic rate. The leptin, an adipose tissue hormone whose plasma levels reflect energy stores, plays an important rule in the pathogenesis of such eating disorders like bulimia and anorexia. Thyroid hormones are major regulators of energy homeostasis. It is possible that leptin and thyroid hormone exert their actions on thermogenesis and energy metabolism via the same common effector patways. Leptin influences feedback regulation of the hypotalamic TRH-secreting neurons by thyroid hormone. Low serum levels of thyroid hormones reflect a dysfunction of the hypotalamic-pituitary-thyroid (HPT) and hypotalamic-pituitary-adrenal (HPA) axis in patients with nervosa anorexia. Neuroendocrine effects of leptin include effects on the HPT and HPA axis. The aim of this work is to evaluated the interactions between leptina and HPT axis on the basis of recent published works and reviews in literature.


Assuntos
Sistema Hipotálamo-Hipofisário/fisiologia , Leptina/fisiologia , Glândula Tireoide/fisiologia , Humanos
9.
J Asthma ; 44(6): 429-32, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17654127

RESUMO

OBJECTIVE: Scientific evidence suggests that lycopene and antioxidant vitamins have significant antioxidant and protective effects. METHODS: This case-control study included 96 subjects (40 asthmatics, 56 healthy control subjects). Baseline blood samples, pulmonary function tests, and clinical and alimentary histories were collected. All subjects were grouped by age, sex, cigarette smoking habit, body mass index, alimentary intake, and atopic status. RESULTS: Serum lycopene concentration was significantly lower in asthmatic subjects than in healthy control subjects (0.10+/-0.7 micromoL/L vs. 0.16+/-0.8 micromoL/L--p<0.001). Serum vitamin A concentration was significantly lower in asthmatics (2.38+/-0.37 micromoL/L) in respect to control subjects (3.06+/-0.56 micromoL/L) (p<0.01). Plasma serum concentration of vitamin E and beta-carotene were not found to be different in the two groups. CONCLUSIONS: Dietary supplementation or adequate intake of lycopene and vitamin A rich foods may be beneficial in asthmatic subjects.


Assuntos
Antioxidantes/análise , Asma/sangue , Carotenoides/sangue , Vitaminas/sangue , Adulto , Análise de Variância , Asma/fisiopatologia , Índice de Massa Corporal , Estudos de Casos e Controles , Ingestão de Energia , Feminino , Volume Expiratório Forçado , Humanos , Licopeno , Masculino , Pessoa de Meia-Idade , Pico do Fluxo Expiratório , Fumar , Capacidade Vital , Vitamina A/sangue , Vitamina E/sangue , beta Caroteno/sangue
10.
Allergy Asthma Proc ; 25(6): 445-8, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15709456

RESUMO

Many studies analyze the effects of many drugs on quality of life (QOL). The aim of this study is to compare the effectiveness of the leukotriene receptor antagonists on QOL. Forty mild asthmatic patients were randomized for 12 treatment-weeks and divided into two groups: the first group was treated with montelukast (MON; 10 mg daily) and the second one was treated with zafirlukast (ZAF; 40 mg daily). All patients underwent clinical examination, spirometry, and completed the Asthma Quality of Life Questionnaire. For each domain, a value of 1 (maximal impairment) and 7 (no impairment) was used. The MON group had in all items a basal median value of 4.7 compared with 5.5 after the treatment (p < 0.05). For physical activities, the mean value was 5.1 compared with 5.9 (p < 0.05). The median scores of 12 symptoms and 5 emotion items were 5.0 and 4.7, significantly lower than 5.7 and 5.3 (p < 0.05). For the environmental stimuli domain, the mean value was 4.6 compared with 5.3 (p < 0.05). The ZAF group had in all items a basal median value of 4.8 compared with 5.7 after the treatment (p < 0.05). For physical activities, the value was 5.0 compared with 5.7 (p < 0.05). Median scores of 12 symptoms and 5 emotions were 4.9 and 4.8, significantly lower than 5.6 and 5.8 (p < 0.05). For the environmental stimuli domain, the median score was 4.7, significantly lower than 5.6 (p < 0.05). The results did not show many differences between the two treatments, showing significant improvement for both MON and ZAF on QOL.


Assuntos
Acetatos/administração & dosagem , Asma/tratamento farmacológico , Antagonistas de Leucotrienos/administração & dosagem , Qualidade de Vida , Quinolinas/administração & dosagem , Compostos de Tosil/administração & dosagem , Administração Oral , Adolescente , Adulto , Asma/diagnóstico , Ciclopropanos , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Seguimentos , Humanos , Indóis , Masculino , Satisfação do Paciente , Fenilcarbamatos , Testes de Função Respiratória , Índice de Gravidade de Doença , Espirometria , Sulfetos , Sulfonamidas , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA